Full text is available at the source.
Sleeve gastrectomy versus dual GLP-1/GIP receptor agonist to improve access to kidney transplantation in patients with end-stage renal disease and obesity: A decision analysis
Comparing weight loss surgery and hormone-based treatment to improve kidney transplant chances in patients with advanced kidney failure and obesity
AI simplified
Abstract
14.74% of patients undergoing sleeve gastrectomy received a kidney transplant within 5 years, the highest among the evaluated interventions.
- Sleeve gastrectomy led to more rapid weight loss, with 27.49% of patients achieving a BMI ≤35 kg/m² by 6 months.
- The predicted transplant rates at 5 years were 9.06% for dual GLP-1/GIP receptor agonist patients and 4.83% for GLP-1 receptor agonist patients.
- Sleeve gastrectomy is associated with a survival advantage, especially in patients with higher pre-intervention BMIs.
- Dual GLP-1/GIP receptor agonist treatment resulted in a significant number of patients undergoing transplantation, indicating its potential as an effective alternative.
AI simplified